THE ANTI-MYELOMA ACTIVITY OF PERK KINASE INHIBITOR IN TARGETING MORE THAN 50 UPR-RELATED GENES INVOLVED IN THE PROLIFERATION OF MM CELLS

EHA Library, Tina Bagratuni, 181007

ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE MYELOMA: MALIGNANT CO-OPTATION OF ARGININE AS NOVEL IMMUNO-METABOLIC CHECKPOINT

EHA Library, ALESSANDRA ROMANO, 181008

ESTIMATED GLOMERULAR FILTRATION (EGFR) CALCULATED BY CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY MORTALITY IN MYELOMA PATIENTS

EHA Library, Eirini Katodritou, 181009

ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS

EHA Library, Alejandra Leivas, 181010

UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS

EHA Library, Spyros Papamichos, 181011

THE RATIO OF PATHOLOGICAL PLASMOCYTES, ASSESSED BY 8-COLOR FLOW CYTOMETRY, PREDICTS OF RISK OF EVOLUTION IN MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND SMOULDERING MULTIPLE MYELOMA.

EHA Library, Ludovic LHERMITTE, 181012

ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION.

EHA Library, Alberto Horenstein, 181013

TREATMENT OPTIMIZATION FOR MULTIPLE MYELOMA: SCHEDULE-DEPENDENT SYNERGISTIC CYTOTOXICITY OF POMALIDOMIDE AND CARFILZOMIB ON AN IN VITRO AND EX-VIVO MODEL

EHA Library, Enrica Borsi, 181014

IMPACT OF POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) MAINTENANCE THERAPY ON OUTCOMES IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING THE LARGE PROSPECTIVE COMMUNITY-BASED CONNECT® MM REGISTRY

EHA Library, Sundar Jagannath, 181015

DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRETREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Prashant Kapoor, 181016

IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA PATIENTS POST STEM CELL TRANSPLANT.

EHA Library, Narjust Duma, 181017

COMPARING WHOLE BODY MRI WITH PET-CT IMAGING AT DIAGNOSIS OF MYELOMA

EHA Library, Ieuan WALKER, 181018

PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Paolo Milani, 181019

RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS

EHA Library, Ruben Niesvizky, 181020

EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING INDUCTION TREATMENT.

EHA Library, Ieuan WALKER, 181021

PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Judith Trotman, 181022

INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED, TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB.

EHA Library, Sara Bringhen, 181023

POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS

EHA Library, David S. Siegel, 181024

“REAL WORLD” DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 181025

EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY IN A LARGE COHORT OF PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB

EHA Library, Barbara Gamberi, 181026

NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS

EHA Library, Nicole Skoetz, 181027

WT1 HETEROCLITIC EPITOPE IMMUNIZATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)

EHA Library, Guenther KOEHNE, 181028

ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH PROGRESSIVE DISEASE AT TIME OF FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION: PREDICTORS OF PROGRESSIVE DISEASE AND FACTORS AFFECTING SURVIVAL

EHA Library, Joanna Blocka, 181029

SEVERE INFECTIONS IMPACTS OVERALL SURVIVAL IN ACTIVE MULTIPLE MYELOMA PATIENTS

EHA Library, Gregorio Barilà, 181030

EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE REAL-WORLD SETTING IN THE UNITED STATES

EHA Library, Clara Chen, 181031

LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

EHA Library, Katrin Kupas, 181032

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP

EHA Library, Iwona Hus, 181033

HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE

EHA Library, Ana BERNI WENNEKERS, 181034

IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS

EHA Library, Luis Gerardo Rodríguez-Lobato, 181035

TREATMENT PATTERNS AND DURATION OF TREATMENT IN JAPANESE MULTIPLE MYELOMA PATIENTS RECEIVING SECOND LINE THERAPY WITH NOVEL AGENTS

EHA Library, Gyungjin Jun, 181036

ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY

EHA Library, Fiorella D'auria, 181037

REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP.

EHA Library, Krzysztof Jamroziak, 181038

REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE

EHA Library, Alonso Fernandez, 181039

FRAILTY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Natalia Schutz, 181040

PROGNOSIS OF AL AMYLOIDOSIS WITH KIDNEY INJURY

EHA Library, Talbot Alexis, 181041

REAL-WORLD DATA ON THE TREATMENT OF RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE AND DEXAMETHASONE IN 2ND LINE (LEGEND STUDY): THE PROGNOSTIC SIGNIFICANCE OF BIOCHEMICAL VS. CLINICAL RELAPSE

EHA Library, Eirini Katodritou, 181042

FDG-PET IN MULTIPLE MYELOMA: DUAL TIME POINT FDG UPTAKE IN FOCAL LESIONS CORRELATE TO RESPONSE TO CHEMOTHERAPY.

EHA Library, Brian Østergaard, 181043

UNDERSTANDING THE CONTRIBUTE OF THE NOTCH PATHWAY IN MULTIPLE MYELOMA BONE MARROW NICHE: A FOCUS ON EXTRACELLULAR VESICLES-MEDIATED COMMUNICATION

EHA Library, Michela Colombo, 181044

THE USE OF CARFILZOMIB AND BORTEZOMIB IN ROUTINE CLINICAL PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL COHORT STUDY IN MULTIPLE MYELOMA

EHA Library, Brian Durie, 181045

ROLE OF SERUM FREE LIGHT CHAIN VS BENCE JONES MEASUREMENT IN LIGHT CHAIN MULTIPLE MYELOMA (LCMM) AT DIAGNOSIS, DURING TREATMENT AND FOLLOW-UP FOR RESPONSE EVALUATION AND RELAPSE DETECTION

EHA Library, Michela Staderini, 181046

SUPPRESSION OF THE NON-MONOCLONAL PAIR AS NEW BIOMARKER OF POOR PROGNOSIS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS AND AFTER AUTOLOGOUS STEM CELL TRANSPLANT

EHA Library, Jose Luis Garcia de Veas Silva, 181047

SURVIVAL STRATIFICATION OF PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA)

EHA Library, ROMAN HAJEK, 181048

REAL-WORLD DATA ON MULTIPLE MYELOMA: A PROSPECTIVE NATIONAL REGISTRY IN URUGUAY ON 224 NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM 2012-2015

EHA Library, Eloísa Riva, 181049

REPRESENTATION OF MINORITIES, THE ELDERLY AND WOMEN IN MULTIPLE MYELOMA CLINICAL TRIALS

EHA Library, Narjust Duma, 181050

EVALUATION OF TREATMENT INDUCED NEUROPATHY IN MULTIPLE MYELOMA AND ITS INFLUENCE ON PHYSICAL AND ROLE FUNCTIONING

EHA Library, S.M.Amine BENLAZAR, 181051

PROGNOSTIC SIGNIFICANCE OF T(11;14) EXPRESSION BY FISH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES

EHA Library, Narjust Duma, 181052

ANALYSIS OF THE CONNECT MM REGISTRY: TREATMENT OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED LENALIDOMIDE MAINTENANCE OR NO MAINTENANCE

EHA Library, Robert M. Rifkin, 181053

SERUM-FREE LIGHT-CHAINS (SFLC) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING LIGHT-CHAIN MULTIPLE MYELOMA (LCMM)

EHA Library, Lucia Lopez-Anglada Fernandez, 181054

TOPSPIN: A NOVEL ALGORITHM TO PREDICT TREATMENT SPECIFIC SURVIVAL IN CANCER

EHA Library, Joske Ubels, 181055

AMYLOIDOSIS RESEARCH CONSORTIUM CARDIAC AMYLOIDOSIS SURVEY: RESULTS FROM PATIENTS WITH AL AMYLOIDOSIS AND THEIR CAREGIVERS

EHA Library, Isabelle Lousada, 181056

EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

EHA Library, Meletios A. Dimopoulos, 181057

TRENDS IN TREATMENT PATTERNS AND SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED 2011-2016 IN THE UNITED STATES USING AN ENHANCED ELECTRONIC HEALTH RECORDS DATABASE

EHA Library, Brian Ung, 181058

HLC PAIR SUPPRESSION AS A RISK FACTOR FOR BLOODSTREAM INFECTIONS AND EARLY DEATH IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Jose Luis Garcia de Veas Silva, 181059

DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

EHA Library, Darko Katalinic, 181060

COMPARISON BETWEEN IMMUNOFIXATION NEGATIVITY AND NORMAL FREE LIGHT CHAIN RATIO WITH MULTICOLOUR FLOW CYTOMETRY FOR RESPONSE ASSESSMENT IN PATIENTS WITH MULTIPLE MYELOMA WITH VGPR OR BETTER

EHA Library, Kentaro Narita, 181061

DARATUMUMAB IS AN EFFECTIVE AND SAFE SALVAGE THERAPY IN RELAPSED/REFRACTORY PATIENTS WITH MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.

EHA Library, Evgeny Klyuchnikov, 181062

PROGNOSTIC RELEVANCE OF VEGF AND VEGFR EXPRESSION IN CD138+/CD19- AND CD138+/CD19+ PLASMA CELLS FROM PATIENTS WITH MONOCLONAL GAMMOPATHIES

EHA Library, Catarina Geraldes dos Santos, 181063

RACIAL DIFFERENCES OF FISH ABNORMALITIES IN MINORITIES WITH MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE

EHA Library, Miguel Gonzalez Velez, 181064

POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE DEXAMETHASONE AS MAINTENANCE FOLLOWING INDUCTION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MYELOMA (ALLG MM14)

EHA Library, Anna Kalff, 181065

POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP

EHA Library, Ludek Pour, 181066

UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE

EHA Library, Trevor Bacon, 181067

RAD REGIMEN AS INDUCTION BEFORE ASCT: OUTCOMES, SAFETY AND EFFECTS ON BONE METABOLISM AND ANGIOGENESIS; FINAL RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 181068

MULTIPLE MYELOMA IN THE REAL WORLD: HOW THERAPEUTIC LANDSCAPE HAS CHANGED IN THE LAST 15 YEARS

EHA Library, Federica Cocito, 181069

CUL4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS

EHA Library, Agata , 181070

MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)

EHA Library, Maxim Solovev, 181071

LONG-TERM OUTCOME OF MULTIPLE MYELOMA (MM) PATIENTS TREATED UP-FRONT WITH SINGLE OR TANDEM AUTOLOGUS STEM CELL TRANSPLANTATION (ASCT) - SINGLE CENTRE EXPERIENCE WITH 334 PATIENTS

EHA Library, Josip Batinic, 181072

EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: CLINICAL IMPACT IN DIAGNOSIS, TREATMENT AND OUTCOME

EHA Library, Adriana Roque, 181073

DIFFERENCES IN PATIENT AND DISEASE CHARACTERISTICS OBSERVED AT INITIATION OF FIRST-LINE AND INITIATION OF SECOND-LINE TREATMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA IN THE CZECH REPUBLIC

EHA Library, Vladimir Maisnar, 181074

AN EARLY GOOD RESPONSE AFTER BORTEZOMIB-BASED INDUCTION REGIMENS REPRESENTS A SIGNIFICANT PREDICTOR FOR IMPROVED PFS IN NDMM PATIENTS

EHA Library, Giulia Rivoli, 181075

RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA

EHA Library, Dinara Makenbaeva, 181076

POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY

EHA Library, Ruth Wester, 181077

INVOLVED/UNINVOLVED HEAVY/LIGHT CHAIN INDEX CAN PREDICT PROGRESSION IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM TRANSPLANT. PRELIMINARY EXPERIENCE

EHA Library, Mercedes Espiño Martinez, 181078

MULTIPLE MYELOMA IMMUNOPHENOTYPIC REMISSION IS A SIGNIFICANT PREDICTOR OF PROGRESSION FREE SURVIVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION - PILOT STUDY

EHA Library, Katerina Beranova, 181079

REGULATION OF NORMAL AND MONOCLONAL IMMUNOGLOBULIN SECRETION BY CYTOKINES (S- SYNDECAN-1, BLYS & TGF-BETA-1) IN PATIENTS WITH IG-SECRETING B-CELL DISORDERS AT PRESENTATION. PROGNOSTIC IMPLICATIONS.

EHA Library, Paraskevi Papaioannou, 181080

PATIENTS WITH MULTIPLE MYELOMA (MM) IN LONG TERM COMPLETE REMISSION (LTCR) AFTER AUTOLOGOUS TRANSPLANT (APBSCT) EXPRESS A DISTINCTIVE INMUNE PROFILE WITH POTENTIAL PROGNOSIS VALUE

EHA Library, Ana Arteche Lopez, 181081

IMPACT OF THE AFFORDABILITY OF NOVEL AGENTS IN PATIENTS WITH MULTIPLE MYELOMA: REAL WORLD DATA ON CURRENT CLINICAL PRACTICE IN MEXICO

EHA Library, Luz Tarin-Arzaga, 181082

BASAL CALCIUM, AN IMPORTANT ELEMENT IN THE DEVELOPMENT OF CALR MUTANT MPNS

EHA Library, Maria Morlan Mairal, 181083

THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Olivera Mitrovic, 181084

CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB?

EHA Library, Lucia Catani, 181085

A COMPARATIVE FUNCTIONAL AND PHENOTYPIC PLATELET ANALYSIS AMONG GENETIC GROUPS OF ESSENTIAL THROMBOCYTHEMIA PATIENTS.

EHA Library, Petros Papadopoulos, 181086

ASSOCIATION ANALYSIS OF CYTOGENETIC AND GENETIC ALTERATIONS IN PRIMARY MYELOFIBROSIS

EHA Library, Rimvydas Norvilas, 181087

FREQUENCY OF CONCURRENT BCR-ABL1, JAK2, CALR AND MPL MUTATIONS IN A COHORT OF 5,545 CASES WITH SUSPECTED MPN BY A DEEP SEQUENCING APPROACH

EHA Library, Sabine Jeromin, 181088

A COMPREHENSIVE ASSESSMENT OF MOLECULAR AND CYTOGENETIC MARKERS OF PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Liubov Poluskina, 181089

JAK2 HAPLOTYPE 46/1 (GGCC) HAS NO EFFECT ON THE PRIMARY RISK OF JAK2 V617F MUTATION, BUT IT STRONGLY POTENTIATES THE PROGRESSION OF GROWN ALLELE BURDEN IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Marina Stolyar, 181090

MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL PCR FOR JAK2V617F DETECTION IN PATIENTS WITH MYELOFIBROSIS (MF) OR ACUTE MYELOID LEUKEMIA SECONDARY TO MF AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Silvia Salmoiraghi, 181091

S100A8/9 ACTIVATION OF MAPK PATHWAY IS SUPPORTED BY ITS RECEPTORS RAGE AND TLR4 IN POLYCYTHEMIA VERA

EHA Library, Marijana Kovacic, 181092

MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS)

EHA Library, Gonzalo Carreno Gomez-Tarragona, 181093

TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES

EHA Library, Sara Galimberti, 181094

PROINFLAMMATORY CYTOKINE IL-6 STIMULATION OF ANGIOGENIC FACTORS AND DNA REPLICATION IS BLOCKED BY JAK-STAT PATHWAY INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Tijana Subotički, 181095

PERCEPTION OF SYMPTOM BURDEN AND TREATMENT GOALS BETWEEN PHYSICIANS AND PATIENTS WITH MPNS: AN ANALYSIS FROM THE INTERNATIONAL MPN LANDMARK SURVEY

EHA Library, Lynda Foltz, 181096

BASELINE QUALITY OF LIFE INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN THE MYELOFIBROSIS: KEY INSIGHTS FROM THE COMFORT-I STUDY

EHA Library, Robyn Scheber, 181097

CHARACTERIZATION OF DISEASE AND OUTCOMES OF PATIENTS WITH MYELOFIBROSIS: A POPULATION BASED STUDY

EHA Library, Jianming He, 181098

SERUM ALBUMIN IS A STRONG PREDICTOR OF SURVIVAL IN MYELOFIBROSIS, INDEPENDENT OF IPSS, DIPSS, AND DIPSS+ SCORES

EHA Library, Andrew Kuykendall, 181099

CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING IN THE MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Waleed Alduaij, 181100

IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 181101

ANALYSES OF 845 PATIENTS WITH PMF, PET-MF AND PPV-MF TREATED IN 35 GERMAN HEMATOLOGY CENTERS – A RETROSPECTIVE FIELD STUDY

EHA Library, Brigitte Kragl, 181102

CALR MUTATION TYPE INFLUENCES THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTEMIA ACCORDING TO A COOPERATIVE STUDY BETWEEN TWO SPANISH CENTERS

EHA Library, Aitor Abuín Blanco, 181103

MONITORING OF LEUKOCYTE-PLATELET AGGREGATES AND SELECTIN LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Dijana Sefer, 181104

HEAT SHOCK PROTEIN 27 EXPRESSION IS INCREASED IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS AND MAY BE AFFECTING THEIR SURVIVAL

EHA Library, R Kusec, 181105

NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERATION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMOCYTHAEMIA MYELOFIBROSIS

EHA Library, Bing Li, 181106